Monte Carlo dosimetry of Y-90 and Ru-106 /Rh-106 disk sources for ocular melanoma treatment: beta dose falloff study
Roya Boudaghi Malidarreh,Hesham M. H. Zakaly,Rahim Khabaz
DOI: https://doi.org/10.1140/epjp/s13360-024-05273-1
2024-06-06
The European Physical Journal Plus
Abstract:Eye plaque brachytherapy, utilizing Y-90 and Ru-106/Rh-106 radionuclides disk sources recently developed for episcleral brachytherapy, proves to be an effective approach for treating eye malignant melanoma. In this work, we have successfully developed a model for melanoma utilizing Y-90 commercially innovative disk source radionuclides. Y-90 disk source has been recently developed by Liberty Vision (LV), NH, USA, and is commercially available now. The Ru-106/Rh-106 disk source has also been simulated based on the Y-90-developed disk source method. Accordingly, this research endeavors to formulate treatment planning guidelines for ocular melanoma, leveraging the distinctive properties of beta particles. These particles demonstrate a swift decrease in dose and possess restricted tissue penetration (beta dose falloff), rendering them particularly suitable for precise and targeted radiotherapy, specifically in the context of malignant melanoma in the eye phantom and skin. A Monte Carlo (MC) simulation study employing the FLAIR environment within FLUKA was executed to evaluate particle contour curves, spectrum, equivalent dose distribution, and consequently beta particle dose falloff in malignant melanoma and vitreous regions for Y-90 and Ru-106/Rh-106 beta emitters. The MC input file, incorporating authentic compositions of an eye phantom, played a crucial role in influencing dosimetric outcomes by providing fluence and dose values by considering possible random events. In addition, the impact of a Titanium (Ti) coating, with a thickness of 0.5 mm, on the generation of bremsstrahlung photons was examined at the cellular level. In this work, the efficacy of commercially pure Y-90 and Ru-106/Rh-106 disk sources was evaluated for melanoma treatment, and simulated results were compared with experimental data, demonstrating a satisfactory agreement for Y-90. Beta spectra analysis of both pure Y-90 and Ru-106/Rh-106 radionuclide sources revealed the generation of high-energy electrons within the tumor volume. The gamma photon spectrum of Ru-106/Rh-106 displayed multiple peaks at specific energy levels, with minimal involvement from low-energy bremsstrahlung photons. Beta dose falloff was observed for both radionuclides based on a reference point of (0 cm, 1.26 cm), emphasizing the superiority of pure Y-90 in brachytherapy. Moreover, the absorbed dose rate and, consequently, the absorbed dose for 20 mCi activity of the Y-90 source were derived at the reference point. This parameter has a significant role in defining the treatment time in brachytherapy. In addition, the obtained result in this method classifies Ru-106/Rh-106 as high dose rate radionuclide, which disagrees with previous published data. The obtained results validate the effectiveness of the MC method in the brachytherapy treatment of eye melanoma, emphasizing the importance of commercially provided disk sources developed by NH. Additionally, this research provides a thorough delineation of the novel Y-90 radionuclide dosimetry within an eye phantom, utilizing a disk source eye plaque method. Nonetheless, no new methodology was presented for Ru-106/Rh-106 disk sources. This constraint stems from the findings, which categorize Ru-106/Rh-106 as radionuclides with high dose rates, thereby suggesting the unsuitability of this approach when employing MC code.
physics, multidisciplinary